Insmed Inc INSM

Healthcare Biotechnology

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

NDAQ:INSM - Post by User

Insmed Inc

Bullboard Posts

Post by queueon Oct 18, 2005 7:09pm

453 Views

Post# 9730651

Tobin Smith

Total loser. Dwells on his one hit wonders and purchases in obvious markets that don't fit his Changewave methodology. Cheesey newsletter writer. Still hyping the Wimax play. It isn't happening. Telcos testing, but they aren't buying. Do some DD Tobey! Alvarian is flogging Redline boxes.

Bullboard Posts

Cybin launches new program phase to treat Major Depressive Disorder